Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $4.85, but opened at $5.04. Maravai LifeSciences shares last traded at $5.05, with a volume of 542,166 shares traded.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. Wolfe Research assumed coverage on shares of Maravai LifeSciences in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Robert W. Baird dropped their price target on Maravai LifeSciences from $10.00 to $9.00 and set an "outperform" rating on the stock in a research note on Friday, November 8th. William Blair reaffirmed a "market perform" rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Guggenheim initiated coverage on shares of Maravai LifeSciences in a research report on Thursday, December 19th. They set a "neutral" rating on the stock. Finally, The Goldman Sachs Group downgraded shares of Maravai LifeSciences from a "neutral" rating to a "sell" rating and reduced their price target for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Maravai LifeSciences currently has a consensus rating of "Hold" and a consensus target price of $10.28.
Check Out Our Latest Analysis on Maravai LifeSciences
Maravai LifeSciences Stock Performance
The company has a market cap of $1.24 billion, a PE ratio of -3.01 and a beta of -0.07. The stock's 50-day simple moving average is $5.65 and its 200 day simple moving average is $7.41. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.
Insider Buying and Selling at Maravai LifeSciences
In related news, insider Carl Hull purchased 175,000 shares of the business's stock in a transaction dated Monday, November 11th. The stock was acquired at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the acquisition, the insider now directly owns 175,000 shares of the company's stock, valued at $987,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.63% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in shares of Maravai LifeSciences by 30.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 506,413 shares of the company's stock worth $3,626,000 after acquiring an additional 117,120 shares during the period. Rhumbline Advisers increased its position in shares of Maravai LifeSciences by 30.4% in the second quarter. Rhumbline Advisers now owns 171,489 shares of the company's stock valued at $1,228,000 after buying an additional 39,955 shares in the last quarter. Choreo LLC acquired a new position in shares of Maravai LifeSciences during the 2nd quarter worth $467,000. Headlands Technologies LLC boosted its position in shares of Maravai LifeSciences by 205.9% in the 2nd quarter. Headlands Technologies LLC now owns 14,935 shares of the company's stock worth $107,000 after buying an additional 10,053 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Maravai LifeSciences by 15.1% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,550,503 shares of the company's stock valued at $32,582,000 after acquiring an additional 598,530 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Recommended Stories
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
